Compare GOTU & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.8M | 407.2M |
| IPO Year | 2019 | 2025 |
| Metric | GOTU | AUTL |
|---|---|---|
| Price | $1.91 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 393.2K | ★ 1.7M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $17.33 | $80.32 |
| Revenue Next Year | $13.02 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.65 | $1.18 |
| 52 Week High | $4.12 | $2.70 |
| Indicator | GOTU | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 63.25 |
| Support Level | $1.86 | $1.27 |
| Resistance Level | $2.03 | $1.98 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 70.83 | 82.69 |
Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.